Use of traditional Chinese medicine (Ren Shen Yang Rong Tang) against microinflammation in hemodialysis patients

An open-label trial

Po Jen Hsiao, Kao Shin Lin, Chih Chien Chiu, Hsueh Wen Chen, Jing Shu Huang, Sen Yeong Kao, Yuh Feng Lin, Jin Shuen Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Complementary and alternative medicine such as traditional Chinese medicine (TCM) is now frequently used combined with Western medicine for treatment in chronic kidney disease (CKD). Objective: We designed an open-label trial to investigate the safety and potential therapeutic effects of Ren Shen Yang Rong Tang (R-S-Y-R-T) in hemodialysis (HD) patients. Methods: The experimental group was treated with additional R-S-Y-R-T combined with routine western medicine, while the control group was treated only with routine western medicine. The duration of study was 6 months. Primary outcomes were to evaluate the changes in serum hematocrit and albumin levels. Secondary outcomes including blood inflammatory markers (c-reactive protein [CRP], interleukin-6 [IL-6], and tumor necrosis factor-α [TNF-α]) were checked. Finally we also followed up the change of quality of life (QOL) in our subjects. Results: Sixty nine respondents were enrolled in this trial. Finally a total of 59 patients (27 R-S-Y-R-T group, 32 control group) completed the 6-month follow-up. Primary outcomes showed no significant statistical change of hematocrit in either 2 group (P>. 0.05). But the R-S-Y-R-T group had a statistical increase in serum albumin (P <0.05). Secondary outcomes were that both TNF-α (p = 0.003) and IL-6 (p = 0.001) showed evident decrease in the R-S-Y-R-T group. CRP was identified without statistical difference in both groups (p = 0.226). The R-S-Y-R-T group also had a significant improvement in QOL (P <0.05). Conclusions: Our study suggests that R-S-Y-R-T could decrease chronic inflammation and increase the life quality in HD patients. Further larger clinical trial of long-term treatment with R-S-Y-R-T is necessary for evaluating treatment use.

Original languageEnglish
Pages (from-to)363-371
Number of pages9
JournalComplementary Therapies in Medicine
Volume23
Issue number3
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Chinese Traditional Medicine
Renal Dialysis
Quality of Life
Complementary Therapies
Hematocrit
Serum Albumin
Interleukin-6
Tumor Necrosis Factor-alpha
Medicine
Control Groups
Therapeutic Uses
Chronic Renal Insufficiency
Proteins
Therapeutics
Clinical Trials
Inflammation
Safety
ren-shen-yang-rong-tang

Keywords

  • Hemodialysis
  • Inflammation
  • Ren Shen Yang Rong Tang
  • Traditional Chinese medicine
  • Treatment effect

ASJC Scopus subject areas

  • Complementary and alternative medicine
  • Advanced and Specialised Nursing
  • Complementary and Manual Therapy

Cite this

Use of traditional Chinese medicine (Ren Shen Yang Rong Tang) against microinflammation in hemodialysis patients : An open-label trial. / Hsiao, Po Jen; Lin, Kao Shin; Chiu, Chih Chien; Chen, Hsueh Wen; Huang, Jing Shu; Kao, Sen Yeong; Lin, Yuh Feng; Chen, Jin Shuen.

In: Complementary Therapies in Medicine, Vol. 23, No. 3, 01.06.2015, p. 363-371.

Research output: Contribution to journalArticle

Hsiao, Po Jen ; Lin, Kao Shin ; Chiu, Chih Chien ; Chen, Hsueh Wen ; Huang, Jing Shu ; Kao, Sen Yeong ; Lin, Yuh Feng ; Chen, Jin Shuen. / Use of traditional Chinese medicine (Ren Shen Yang Rong Tang) against microinflammation in hemodialysis patients : An open-label trial. In: Complementary Therapies in Medicine. 2015 ; Vol. 23, No. 3. pp. 363-371.
@article{d6ea94f1c170442888fdf2aad55fef45,
title = "Use of traditional Chinese medicine (Ren Shen Yang Rong Tang) against microinflammation in hemodialysis patients: An open-label trial",
abstract = "Background: Complementary and alternative medicine such as traditional Chinese medicine (TCM) is now frequently used combined with Western medicine for treatment in chronic kidney disease (CKD). Objective: We designed an open-label trial to investigate the safety and potential therapeutic effects of Ren Shen Yang Rong Tang (R-S-Y-R-T) in hemodialysis (HD) patients. Methods: The experimental group was treated with additional R-S-Y-R-T combined with routine western medicine, while the control group was treated only with routine western medicine. The duration of study was 6 months. Primary outcomes were to evaluate the changes in serum hematocrit and albumin levels. Secondary outcomes including blood inflammatory markers (c-reactive protein [CRP], interleukin-6 [IL-6], and tumor necrosis factor-α [TNF-α]) were checked. Finally we also followed up the change of quality of life (QOL) in our subjects. Results: Sixty nine respondents were enrolled in this trial. Finally a total of 59 patients (27 R-S-Y-R-T group, 32 control group) completed the 6-month follow-up. Primary outcomes showed no significant statistical change of hematocrit in either 2 group (P>. 0.05). But the R-S-Y-R-T group had a statistical increase in serum albumin (P <0.05). Secondary outcomes were that both TNF-α (p = 0.003) and IL-6 (p = 0.001) showed evident decrease in the R-S-Y-R-T group. CRP was identified without statistical difference in both groups (p = 0.226). The R-S-Y-R-T group also had a significant improvement in QOL (P <0.05). Conclusions: Our study suggests that R-S-Y-R-T could decrease chronic inflammation and increase the life quality in HD patients. Further larger clinical trial of long-term treatment with R-S-Y-R-T is necessary for evaluating treatment use.",
keywords = "Hemodialysis, Inflammation, Ren Shen Yang Rong Tang, Traditional Chinese medicine, Treatment effect",
author = "Hsiao, {Po Jen} and Lin, {Kao Shin} and Chiu, {Chih Chien} and Chen, {Hsueh Wen} and Huang, {Jing Shu} and Kao, {Sen Yeong} and Lin, {Yuh Feng} and Chen, {Jin Shuen}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.ctim.2015.03.002",
language = "English",
volume = "23",
pages = "363--371",
journal = "Complementary Therapies in Medicine",
issn = "0965-2299",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Use of traditional Chinese medicine (Ren Shen Yang Rong Tang) against microinflammation in hemodialysis patients

T2 - An open-label trial

AU - Hsiao, Po Jen

AU - Lin, Kao Shin

AU - Chiu, Chih Chien

AU - Chen, Hsueh Wen

AU - Huang, Jing Shu

AU - Kao, Sen Yeong

AU - Lin, Yuh Feng

AU - Chen, Jin Shuen

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background: Complementary and alternative medicine such as traditional Chinese medicine (TCM) is now frequently used combined with Western medicine for treatment in chronic kidney disease (CKD). Objective: We designed an open-label trial to investigate the safety and potential therapeutic effects of Ren Shen Yang Rong Tang (R-S-Y-R-T) in hemodialysis (HD) patients. Methods: The experimental group was treated with additional R-S-Y-R-T combined with routine western medicine, while the control group was treated only with routine western medicine. The duration of study was 6 months. Primary outcomes were to evaluate the changes in serum hematocrit and albumin levels. Secondary outcomes including blood inflammatory markers (c-reactive protein [CRP], interleukin-6 [IL-6], and tumor necrosis factor-α [TNF-α]) were checked. Finally we also followed up the change of quality of life (QOL) in our subjects. Results: Sixty nine respondents were enrolled in this trial. Finally a total of 59 patients (27 R-S-Y-R-T group, 32 control group) completed the 6-month follow-up. Primary outcomes showed no significant statistical change of hematocrit in either 2 group (P>. 0.05). But the R-S-Y-R-T group had a statistical increase in serum albumin (P <0.05). Secondary outcomes were that both TNF-α (p = 0.003) and IL-6 (p = 0.001) showed evident decrease in the R-S-Y-R-T group. CRP was identified without statistical difference in both groups (p = 0.226). The R-S-Y-R-T group also had a significant improvement in QOL (P <0.05). Conclusions: Our study suggests that R-S-Y-R-T could decrease chronic inflammation and increase the life quality in HD patients. Further larger clinical trial of long-term treatment with R-S-Y-R-T is necessary for evaluating treatment use.

AB - Background: Complementary and alternative medicine such as traditional Chinese medicine (TCM) is now frequently used combined with Western medicine for treatment in chronic kidney disease (CKD). Objective: We designed an open-label trial to investigate the safety and potential therapeutic effects of Ren Shen Yang Rong Tang (R-S-Y-R-T) in hemodialysis (HD) patients. Methods: The experimental group was treated with additional R-S-Y-R-T combined with routine western medicine, while the control group was treated only with routine western medicine. The duration of study was 6 months. Primary outcomes were to evaluate the changes in serum hematocrit and albumin levels. Secondary outcomes including blood inflammatory markers (c-reactive protein [CRP], interleukin-6 [IL-6], and tumor necrosis factor-α [TNF-α]) were checked. Finally we also followed up the change of quality of life (QOL) in our subjects. Results: Sixty nine respondents were enrolled in this trial. Finally a total of 59 patients (27 R-S-Y-R-T group, 32 control group) completed the 6-month follow-up. Primary outcomes showed no significant statistical change of hematocrit in either 2 group (P>. 0.05). But the R-S-Y-R-T group had a statistical increase in serum albumin (P <0.05). Secondary outcomes were that both TNF-α (p = 0.003) and IL-6 (p = 0.001) showed evident decrease in the R-S-Y-R-T group. CRP was identified without statistical difference in both groups (p = 0.226). The R-S-Y-R-T group also had a significant improvement in QOL (P <0.05). Conclusions: Our study suggests that R-S-Y-R-T could decrease chronic inflammation and increase the life quality in HD patients. Further larger clinical trial of long-term treatment with R-S-Y-R-T is necessary for evaluating treatment use.

KW - Hemodialysis

KW - Inflammation

KW - Ren Shen Yang Rong Tang

KW - Traditional Chinese medicine

KW - Treatment effect

UR - http://www.scopus.com/inward/record.url?scp=84937636145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937636145&partnerID=8YFLogxK

U2 - 10.1016/j.ctim.2015.03.002

DO - 10.1016/j.ctim.2015.03.002

M3 - Article

VL - 23

SP - 363

EP - 371

JO - Complementary Therapies in Medicine

JF - Complementary Therapies in Medicine

SN - 0965-2299

IS - 3

ER -